MSD Announces HPS2-THRIVE Study of TREDAPTIVE™ (modified-release nicotinic acid/laropiprant) Did Not Achieve Primary Endpoint

  MSD Announces HPS2-THRIVE Study of TREDAPTIVE™ (modified-release nicotinic
  acid/laropiprant) Did Not Achieve Primary Endpoint

Business Wire

WHITEHOUSE STATION, N.J. -- December 20, 2012

MSD, known as Merck (NYSE: MRK) in the United States and Canada, today
announced that the HPS2-THRIVE (Heart Protection Study 2-Treatment of HDL to
Reduce the Incidence of Vascular Events) study of TREDAPTIVE^™
(modified-release nicotinic acid/laropiprant) did not meet its primary
endpoint. MSD and the investigators are informing regulatory agencies of these
results. The company is also preparing communications to health care providers
in countries where the medicine is currently available, and will continue to
work with regulators to provide updated information to health care providers.
Based on the current understanding of these new data and until further
analyses can be completed, MSD is recommending that providers not start new
patients on TREDAPTIVE. MSD does not plan to seek regulatory approval for the
medicine in the United States.

HPS2-THRIVE was independently conducted by the Clinical Trial Service Unit at
Oxford University and funded by MSD. The study enrolled 25,673 patients
considered to be at high risk for cardiovascular events. Of those enrolled,
14,741 were from Europe (the United Kingdom and Scandinavia) and 10,932 were
from China. Patients in the study were followed for a median of 3.9 years.
HPS2-THRIVE compared modified release nicotinic acid and laropiprant plus
statin therapy versus statin therapy. It was not designed to assess directly
the separate effects of either modified-release nicotini acid or laropiprant.

In the study, adding the combination of modified-release nicotinic acid and
laropiprant to statin therapy did not significantly further reduce the risk of
the combination of coronary deaths, non-fatal heart attacks, strokes or
revascularizations compared to statin therapy. In addition, there was a
statistically significant increase in the incidence of some types of non-fatal
serious adverse events in the group that received modified-release nicotinic
acid/laropiprant.

With the agreement of the independent research team at Oxford University, MSD
is sharing results from the study with regulatory agencies in countries where
the medicine is approved (under the brand names TREDAPTIVE or CORDAPTIVE) and
in other countries as well. The investigators are conducting additional
analyses, including regional analyses, to further understand the results. They
anticipate reporting the detailed study results in the first quarter of 2013.

"While we are disappointed in these results, we thank the investigators who
have conducted the study and the patients who have participated in it,” said
Peter S. Kim, Ph.D., president, Merck Research Laboratories. “We are committed
to working closely with the independent research team at Oxford University and
with regulatory agencies to understand the results and determine next steps."

MSD encourages patients with any concerns to speak to their physician.

About TREDAPTIVE/CORDAPTIVE

TREDAPTIVE/CORDAPTIVE has been approved in approximately 70 countries,
including in Europe, and is sold in approximately 40 countries. TREDAPTIVE is
also sold under the brand names PELZONT in Italy and TREVACLYN in Italy and
Portugal. Sales through the first three quarters of 2012 were approximately
$13 million.

Selected Product Information About TREDAPTIVE

Therapeutic Indications

TREDAPTIVE is indicated for the treatment of dyslipidemia, particularly in
patients with combined mixed dyslipidemia (characterized by elevated levels of
LDL-C and TG and low HDL-C) and in patients with primary hypercholesterolemia
(heterozygous familial and nonfamilial).

TREDAPTIVE should be used in patients in combination with HMG-CoA reductase
inhibitors (statins), when the cholesterol-lowering effect of statin
monotherapy is inadequate. It can be used as monotherapy only in patients in
whom statins are considered inappropriate or not tolerated. Diet and other
nonpharmacological treatments (e.g., exercise, weight reduction) should be
continued during therapy with TREDAPTIVE.

Selected Safety Information About TREDAPTIVE

TREDAPTIVE is contraindicated in patients with hypersensitivity to the active
substances or to any of the excipients, significant or unexplained hepatic
dysfunction, active peptic ulcer disease, or arterial bleeding.

The most common side effect of TREDAPTIVE is flushing (skin redness, warmth,
and itching). Other common side effects include dizziness, headache,
paresthesia, diarrhea, dyspepsia, nausea, vomiting, erythema, pruritus, rash,
urticaria, feeling hot, and elevations in ALT or AST (consecutive, ≥ 3X ULN),
fasting glucose, and uric acid.

Liver function tests are recommended before initiation, every 6 to 12 weeks
for the first year, and periodically (e.g., semiannually) thereafter. Should
an increase in ALT or AST of ≥3X ULN persist, reduction of dose or withdrawal
of TREDAPTIVE is recommended

Physicians contemplating combined therapy with statins and TREDAPTIVE should
carefully weigh the potential benefits and risks and should carefully monitor
patients for myopathy (muscle pain, tenderness, or weakness), particularly
during the initial months of therapy and when the dose of either drug is
increased (periodic serum CK should be considered in such situations).

If muscle pain, weakness, or cramps occur while a patient is receiving
TREDAPTIVE with a statin, their CK levels should be measured. If these levels
are found, in the absence of strenuous exercise, to be significantly elevated
(> 5X ULN), treatment should be stopped.

Caution should be used when treating Chinese patients with TREDAPTIVE
coadministered with simvastatin or ezetimibe/simvastatin (particularly
simvastatin doses of 40mg or higher) because of a higher than expected
incidence of myopathy in those patients. Because the risk of myopathy with
statins is dose-related, the use of TREDAPTIVE with simvastatin 80 mg or
ezetimibe/simvastatin 10/80 mg is not recommended in Chinese patients. It is
unknown whether there is an increased risk of myopathy in other Asian patients
treated with TREDAPTIVE coadministered with simvastatin or ezetimibe/
simvastatin.

Diabetic or potentially diabetic patients should be observed closely.
Adjustment of diet and/or hypoglycemic therapy may be necessary. TREDAPTIVE
should be used with caution in patients with renal dysfunction, acute coronary
syndrome, risk for hypophosphatemia, or gout (or predisposed to gout). As with
other nicotinic acid products, TREDAPTIVE was associated with a small
reduction in platelet count. Therefore, patients undergoing surgery should be
carefully evaluated. Patients with a history of jaundice, hepatobiliary
disorder, or peptic ulcer should be observed closely.

A clinical study to evaluate the effect of laropiprant on platelet function in
patients concomitantly receiving both acetylsalicylic acid and clopidogrel was
inconclusive. Because this study did not rule out the potential for
prolongation of bleeding time, patients receiving TREDAPTIVE concomitantly
with acetylsalicylic acid and clopidogrel should be closely monitored.

About MSD

Today's MSD is a global healthcare leader working to help the world be well.
MSD is known as Merck inside the United States and Canada. Through our
prescription medicines, vaccines, biologic therapies, and consumer care and
animal health products, we work with customers and operate in more than 140
countries to deliver innovative health solutions. We also demonstrate our
commitment to increasing access to healthcare through far-reaching policies,
programs and partnerships. For more information, visit www.merck.com and
connect with us on Twitter, Facebook and YouTube.

Forward-Looking Statement

This news release includes “forward-looking statements” within the meaning of
the safe harbor provisions of the United States Private Securities Litigation
Reform Act of 1995. These statements are based upon the current beliefs and
expectations of MSD’s management and are subject to significant risks and
uncertainties. If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially from those set
forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest rate
and currency exchange rate fluctuations; the impact of pharmaceutical industry
regulation and health care legislation in the United States and
internationally; global trends toward health care cost containment;
technological advances, new products and patents attained by competitors;
challenges inherent in new product development, including obtaining regulatory
approval; MSD’s ability to accurately predict future market conditions;
manufacturing difficulties or delays; financial instability of international
economies and sovereign risk; dependence on the effectiveness of MSD’s patents
and other protections for innovative products; and the exposure to litigation,
including patent litigation, and/or regulatory actions.

MSD undertakes no obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or otherwise. Additional
factors that could cause results to differ materially from those described in
the forward-looking statements can be found in MSD’s/Merck’s 2011 Annual
Report on Form 10-K and the company’s other filings with the Securities and
Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

Contact:

MSD
Media Contacts:
Pamela Eisele, 908-423-5042
Skip Irvine, 267-305-5397
or
Investor Contact:
Carol Ferguson, 908-423-4465
 
Press spacebar to pause and continue. Press esc to stop.